Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant.

ABSTRACT: Allogeneic transplant remains the best postremission therapy for patients with nonfavorable risk acute myeloid leukemia (AML). However, some patients are ineligible because of psychosocial barriers, such as lack of appropriate caregiver support. We hypothesized that immune checkpoint inhibition after autologous transplant might represent effective postremission therapy in such patients. We conducted a phase 2 study of autologous transplantation followed by administration of pembrolizumab (8 cycles starting day +1). Twenty patients with nonfavorable AML in complete remission were treated (median age, 64 years; CR1, 80%); 55% were non-White and adverse-risk AML was present in 40%. Treatment was well tolerated, with only 1 nonrelapse death. Immune-related adverse events occurred in 9 patients

SUBMITTER: Solomon SR 

PROVIDER: S-EPMC10500475 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature